The largest community of pharma leaders

HighTide Therapeutics to Present Phase 2 Results of HTD1801 in NASH Patients Co-Morbid with Type 2 Diabetes at NASH Summit

SHENZHEN, China & ROCKVILLE, Md.–(BUSINESS WIRE)–HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Adrian M. Di Bisceglie, Chief Medical Officer, will present at the digital 4th Annual NASH Summit on Wednesday, December 16, 2020 at 3 p.m. EST. HighTide will show the results of their Phase 2 study of HTD1801 in adults with non-alc

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles